Close Menu

People in the News

Mar 03, 2021

Omniome: Thomas O'Lenic

Sequencing firm Omniome has appointed Thomas O'Lenic as chief commercial officer. O'Lenic previously held commercial, general manager, and executive leadership positions with Advanced Cell Diagnostics (now part of Bio-Techne); IntegenX (now part of Thermo Fisher Scientific); Molecular Devices (a Danaher company); PerSeptive Biosystems, Millipore, and FreeSlate.

Mar 03, 2021

Geneoscopy: Vince Wong

Geneoscopy has appointed Vince Wong as it Chief Commercial Officer. Wong previously served as VP of sales at Roche Diagnostics. He has also served as VP and general manager of physician office and specialty diagnostics at the firm. 

Mar 03, 2021

Transplant Genomics: Nicholas Grund, John Slaught, Charles Argentine

Transplant Genomics has appointed Nicholas Grund as President, John Slaught as vice president of sales, and Charles Argentine as director of clinical operations.

Grund will be responsible for developing and implementing new strategies to grow Transplant Genomics' existing business, expanding the company's TruGraf portfolio into new organ types, and working with customers, advocates, and payors to establish long term relationships. He will head company initiatives to increase TruGraf usage in the community-based nephrology market, and will also shepherd the launch of TruGraf Liver in the second half of 2021.

Grund has more than 25 years of commercial leadership experience in the biopharmaceutical industry, including several global executive roles in finance, sales, and marketing. He previously served as chief commercial officer at AMAG Pharmaceuticals, and also spent 13 years at Sanofi, most recently as the leader of the company's rare disease and multiple sclerosis franchises in the Asia Pacific region and Canada. 

Slaught has more than 25 years of commercial team leadership. He most recently served as VP of sales for Optum.

Argentine has more than 15 years of laboratory management experience, primarily in the areas of genetic sequencing and immunology. He most recently served as director of clinical laboratory operations at Roche Sequencing Solutions.

Mar 03, 2021

Arbor Biotechnologies: Mark Angelino

Arbor Biotechnologies has appointed Mark Angelino to its board of directors. 

Angelino has more than 20 years of expertise in working with numerous pharmaceutical companies, Arbor said. He was the cofounder and chief operating officer of Generation Bio from 2016 until 2021, and has also served as as senior vice president of pharmaceutical sciences and the rare disease franchise head at bluebird bio from 2012 until 2016. He also served as senior director of R&D and site head in Cambridge, Massachusetts for Baxter Healthcare from 2010 to 2012. 

Mar 03, 2021

Seven Bridges: David Ledbetter, Neil Martin, Chris Mattman

Seven Bridges has created a strategic advisory board and named three members. David Ledbetter, chief clinical officer at Dascena, is a former executive VP and chief scientific officer at Geisinger Health System and a longtime professor of human genetics. Neurosurgeon Neil Martin is director of quality and innovation at Pacific Neuroscience Institute Foundation and previously ran the neuroscience institute at Geisinger. Chris Mattman is division manager of the AI, Analytics, and Innovative Development Organization in the IT section of NASA's Jet Propulsion Laboratory, and also is director of the information retrieval and data science group at the University of Southern California.

Mar 01, 2021

GA4GH: Susan Fairley

The Global Alliance for Genomics and Health (GA4GH) has named Susan Fairley the group's first-ever chief standards officer. As such, Fairley will oversee standards development work by GA4GH's technical staff and by more than 200 external contributors. Fairley, who will be based at the European Molecular Biology Laboratory's European Bioinformatics Institute in Cambridge, UK, formerly was project lead for EMBL-EBI's International Genome Sample Resource.

Mar 01, 2021

ERS Genomics: Jon Kratochvil

ERS Genomics has appointed Jon Kratochvil as vice president for business development and licensing for North America. Kratochvil previously served as director of business development and licensing at MilliporeSigma, where he was responsible for global development opportunities for the company's gene editing and novel modalities technologies. He has also previously served as business development director for Washington University, and as licensing manager and competitive intelligence analyst for Abbott Laboratories' diagnostics division.

Feb 24, 2021

Ultivue: Mike Sismour, Mark Rees

Ultivue, a company specializing in multiplex biomarker assays for tissue phenotyping and digital pathology, has appointed Mike Sismour as vice president, research, and Mark Rees as vice president, corporate development.

Sismour most recently served as chief scientist/head of genomics R&D at Beckman Coulter Life Science. He was a National Institutes of Health Ruth L. Kirschstein postdoc at Harvard Medical School and a fellow at Harvard's Wyss Institute.

Rees most recently worked for StatLab where he helped create a diagnostic division. He previously held leadership roles in commercial development, scientific affairs, and R&D at Enzo Life Sciences, Leica Biosystems (Danaher), and Novocastra Laboratories.

Feb 23, 2021

908 Devices: Jeff George, Fenel Eloi

Mass spectrometry firm 908 Devices has appointed Jeff George and Fenel Eloi to its board of directors.

George has previously served as the global division head and CEO of two divisions of Novartis, Sandoz, and Alcon from 2008 to 2016. In parallel, he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharmaceutical, Dorian Therapeutics, and Wishbone Medical.

Eloi previously served as CFO then COO at Cell Signaling Technology. He also serves on the board of directors of MitoTherapeutix.

Feb 23, 2021

ImmunoScape: Geoff Nosrati

Singapore-based immune profiling company ImmunoScape has named Geoff Nosrati as chief business officer in conjunction with the establishment of the firm's US headquarters in San Diego. Before joining ImmunoScape, Nosrati advised biotechnology clients at McKinsey & Co. He also held senior executive positions at Aduro Biotech. Nosrati holds a PhD in biochemistry and molecular biology from the University of California, Los Angeles.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

Feb 19, 2021

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.

Feb 19, 2021

Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.

Feb 18, 2021

Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.

Feb 18, 2021

Delfi Diagnostics: Tara Maddala, Allison Ryan

Delfi Diagnostics has appointed Tara Maddala as its VP of clinical development and Allison Ryan as VP of data science. Maddala previously served as VP of biostatistics and data managment at Grail. Ryan previously served as VP of data science at Natera. 

Feb 17, 2021

Seer: Deep Nishar, Mostafa Ronaghi

Proteomics company Seer has appointed Deep Nishar and Mostafa Ronaghi to its board of directors. Nishar is a senior managing partner at SoftBank Investment Advisers. Prior to that, he was senior VP of products and user experience at LinkedIn and held senior executive roles at Google. He is also the founder of enterprise software company Patkai Networks.

Ronaghi is the former chief technology officer, senior VP of entrepreneurial development, and senior VP of Illumina. He is also a cofounder of Grail, the Illumina Accelerator, Avantome, NextBio, ParAllele Bioscience, and Pyrosequencing, as well as a current scientific advisory member of Seer.

Feb 16, 2021

NephroSant: Mark Capone

Mark Capone has joined the board of directors of NephroSant, a spinout from the University of California, San Francisco that is developing noninvasive testing solutions for kidney health. He is the president and CEO of Precision Medicine Advisors. Before that, he was president and CEO of Myriad Genetics, and prior to that, he held various positions at Eli Lilly. Capone holds a BS in chemical engineering from Penn State University and an MS in chemical engineering and in management from the Massachusetts Institute of Technology.

Feb 16, 2021

1health: Mostafa Ronaghi

Testing-as-a-service company 1health has appointed Mostafa Ronaghi to its board of directors. Ronaghi was chief technology and senior vice president at Illumina for about 13 years. He also cofounded the Illumina Accelerator and spinoff company Grail. Ronaghi also cofounded several other genomics and life science data ventures, including Avantome, ParAllele Bioscience, NextBio, and Pyrosequencing. Prior to these ventures, he was a principal investigator at Stanford University from 1999 to 2008, focusing on the development of molecular diagnostic applications.

Feb 12, 2021

LexaGene: Daryl Rebeck, Stephen Mastrocola

LexaGene said this week that Daryl Rebeck will resign from the company's board and his position as president effective Feb. 15. The company also said that Stephen Mastrocola has joined the board of directors. Mastrocola recently retired from Ernst & Young after 19 years, where he was a senior assurance partner and led the firm's New England Assurance Practice for several years. Prior to this, he was an assurance partner at Arthur Andersen.

Feb 11, 2021

GenomSys: Alessio Ascari

GenomSys has hired longtime digital health consultant Alessio Ascari as CEO. Ascari joins the Lausanne, Switzerland-based bioinformatics startup after running his own consultancy as well as leading a digital therapeutics startup that helps patients manage blood pressure. He is a former leader of McKinsey's global mobile health initiative. 

Feb 11, 2021

Sophia Genetics: Ross Muken

Sophia Genetics has named Ross Muken as chief financial officer. Muken, who has more than two decades of experience in finance, previously had been CFO and COO of Click Therapeutics. He has also had stints as head of healthcare services and technology research at Evercore ISI and in equity research at Thomas Weisel Partners. 

Feb 10, 2021

Sema4: Nat Turner, Emily Leproust, Eli Casdin

Sema4 has appointed three new members to its board of directors, who will take up their posts after the firm has gone public through a planned merger with special purpose acquisition company CM Life Sciences.

The new members are Nat Turner, cofounder and CEO of Flatiron Health; Emily Leproust, cofounder and CEO of Twist Bioscience; and Eli Casdin, founder and chief investment officer of Casdin Capital.

Feb 10, 2021

908 Devices: Steve Davenport

908 Devices, a developer of miniature mass spectrometers for chemical and biomolecular analysis, has appointed Steve Davenport as vice president of commercial sales.  Davenport previously worked in the life sciences division at Sartorius. He has also previously held sales positions at Amersham Pharmacia Biotech (now Cytiva); Molecular Devices (now Danaher); and ProteinSimple (now Bio-Techne).

Feb 10, 2021

Qiagen: Toralf Haag

Qiagen said this week that it has appointed Toralf Haag as a member of the supervisory board and audit committee. Since October 2018 Haag has served as CEO and chairman of management board at Voith, a global technology company. Before joining Voith, he served for more than 11 years at Lonza as CFO and a member of the executive committee.

Feb 09, 2021

Caribou Biosciences: Jason O'Byrne

Jason O'Byrne has been appointed as CFO of Caribou Biosciences. Most recently, he was senior VP of finance at Audentes Therapeutics. Prior to that, he was APA regional CFO at Genentech/Roche. O'Byrne holds a bachelor of applied science in mechanical engineering from the University of British Columbia and an MBA in finance from New York University.

Pages

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.